N
164.85
19.50 (13.42%)
| Penutupan Terdahulu | 145.35 |
| Jumlah Dagangan | 4,056,105 |
| Harga / Pendapatan (P/E Ke hadapan) | 16.80 |
| Harga / Jualan (P/S) | 4.48 |
| Harga / Buku (P/B) | 4.02 |
| Julat 52 Minggu |
| Margin Keuntungan | 12.68% |
| Margin Operasi (TTM) | 4.14% |
| EPS Cair (TTM) | 2.95 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -81.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.45% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | 529.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 235.48 M |
| Pulangan Atas Aset (ROA TTM) | 8.75% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Neurocrine Biosciences, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.1 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Penilaian Relatif | 5.0 |
| Kesihatan Kewangan | 3.9 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 1.09 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 98.86% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |